Yüklüyor......

Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study

BACKGROUND: Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of icatibant is not documented in the...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Transl Allergy
Asıl Yazarlar: Caballero, Teresa, Zanichelli, Andrea, Aberer, Werner, Maurer, Marcus, Longhurst, Hilary J., Bouillet, Laurence, Andresen, Irmgard
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2018
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5870812/
https://ncbi.nlm.nih.gov/pubmed/29599966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13601-018-0195-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!